Daily Respiratory Research Analysis
Analyzed 133 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies span implementation science, diagnostic innovation, and public health equity. A German multicenter registry shows large institution-driven variability in molecular testing for advanced NSCLC with survival implications, a prospective multi-centre trial demonstrates high-yield, radiation-free robotic bronchoscopy for challenging peripheral nodules, and a nationwide Korean cohort reveals markedly higher long-term mortality among tuberculosis survivors with disabilities.
Research Themes
- Implementation of precision oncology in respiratory cancers
- Minimally invasive, radiation-free diagnostics for peripheral pulmonary nodules
- Health disparities and long-term outcomes in post-tuberculosis care
Selected Articles
1. Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315).
In a large German registry of 6,437 advanced NSCLC patients, the treating institution explained 21.4% of the variance in actionable genomic testing, with predicted testing probabilities ranging from 30.5% to 93.2% across centers. Lack of testing was independently associated with worse overall survival. Results underscore practice-level drivers of precision oncology implementation.
Impact: Quantifying institution-driven variability with survival impact provides actionable targets for system-level quality improvement in thoracic oncology.
Clinical Implications: Embed standardized, audited molecular testing pathways across institutions, monitor testing rates via registries, and incorporate institutional performance metrics into quality programs to ensure equitable access to targeted therapies.
Key Findings
- Actionable genomic testing was performed in 77.9% of advanced NSCLC patients across 171 institutions.
- Institutional factors accounted for 21.4% of variance in testing (intraclass correlation), with probabilities ranging 30.5–93.2%.
- Lack of testing was independently associated with worse overall survival (adjusted HR 1.11).
- Variability was more pronounced in squamous histology (ICC 29.5%) and KRAS testing (ICC 34.4%).
Methodological Strengths
- Prospective, multicenter real-world registry with large sample size (n=6,437).
- Robust mixed-effects modeling quantifying institutional variance (ICC) and adjusted survival analyses.
Limitations
- Observational design limits causal inference; residual confounding may persist.
- Generalizability may be influenced by national practice patterns within Germany.
Future Directions: Evaluate targeted implementation interventions (e.g., reflex testing, electronic order sets) in pragmatic trials and expand auditing frameworks to reduce institution-driven disparities.
BACKGROUND: Molecular testing in NSCLC is essential for treatment selection, yet routine implementation remains inconsistent across institutions. Clinical evidence suggests that variability in testing may not be explained by patient or tumor characteristics but might be driven by institutional factors, potentially leading to adverse outcomes. We examined the extent to which variability in AGA testing is attributable to the treating institution. METHODS: We analyzed 6437 adults with stage IIIB/C or IV NSCLC enrolled in the prospective German real-world registry CRISP (2016-2022). Logistic mixed-effects models with AGA testing as the primary outcome were used to determine institutional variability across 171 institutions. Models included patient, tumor, and treatment-related fixed effects with institutions as random effects. Intraclass correlations (ICC) quantified institutional variability unexplained by other covariates. Institution type was tested in secondary analysis, and overall survival in exploratory analysis. FINDINGS: AGA testing was performed in 77.9 % of patients (n = 5016). Predicted probabilities for testing use ranged from 30.5 % to 93.2 % across institutions. Institutions significantly influenced testing use (p < 0.001), accounting for 21.4 % of the total variance. Variability significantly differed by institution type and was more pronounced in subgroups, e.g., squamous histology (ICC 29.5 %) and KRAS testing (ICC 34.4 %). Absence of AGA testing was independently associated with inferior survival (HRadj 1.11, 95 % CI 1.01-1.23, p = 0.029). INTERPRETATION: Substantial institutional variability exists in AGA testing for NSCLC, which was unexplained by patient or tumor characteristics. This objective evaluation of institution-based variability in testing may emphasize the importance of practice patterns on patient care and may therefore provide an avenue for change.
2. Dual-correction robotic bronchoscopy system with ultra-thin catheter for diagnosing challenging peripheral pulmonary nodules: A multi-centre prospective trial.
A multicenter prospective trial of a dual-correction robotic bronchoscopy system with ultra-thin catheters achieved 100% navigation and sampling success and an 84.2% diagnostic yield for challenging peripheral pulmonary nodules, with 88.3% sensitivity for malignancy and zero pneumothorax, all without radiation guidance.
Impact: This platform offers a radiation-free, high-yield alternative for biopsying small, pleural-contact, and reverse-angle nodules, potentially reducing reliance on CT-guided transthoracic procedures.
Clinical Implications: Adoption of robotic bronchoscopy with ultra-thin catheters may expand bronchoscopic access to challenging nodules while minimizing pneumothorax risk and radiation exposure, optimizing diagnostic pathways in lung cancer workups.
Key Findings
- 100% navigation and sampling success in 89 patients with challenging peripheral pulmonary nodules.
- Overall diagnostic yield of 84.2% and malignancy sensitivity of 88.3% without radiation guidance.
- Zero pneumothorax and robust performance across nodules ≤20 mm, pleural-contact, and reverse-angle (≤90°) configurations.
Methodological Strengths
- Prospective, multicenter design with predefined challenging-nodule criteria.
- Comprehensive reporting of navigation/sampling success and safety outcomes under radiation-free conditions.
Limitations
- Single-arm study without head-to-head comparison to alternative navigation platforms or CT-guided biopsy.
- Modest sample size and limited follow-up for downstream clinical outcomes.
Future Directions: Conduct randomized or matched comparative studies versus cone-beam CT–guided bronchoscopy and CT-guided transthoracic biopsy, and assess cost-effectiveness and workflow integration.
BACKGROUND: Conventional bronchoscopy has imited diagnostic yield for challenging peripheral pulmonary nodules(C-PPNs), particularly for small (≤20 mm), pleural-contact, or reverse-angle (bifurcation angle ≤90°) nodules. This prospective multi-centre study evaluates the novel robotic bronchoscopy system (RBS) with ultra-thin catheters in C-PPNs under radiation-free conditions. METHODS: This multi-centre, prospective study enrolled 89 patients with C-PPN (characterised by a diameter ≤20 mm, pleural-contact, or an angle ≤90°) from three centres, who underwent RBS biopsy between 2022 and 2024. Diagnostic yield were conducted based on specific nodule characteristics. Univariate and multivariate logistic regressions were performed to evaluate the association between nodular-related factors and diagnostic yield. RESULTS: The average nodule size was 19.54 mm (53.9%, ≤20 mm). Pleural-contact was observed in 71.9% of nodules, and 64.0% exhibited a reverse-angle (≤90°). The novel system achieved 100% navigation and sampling success. Importantly, the diagnostic yield reached 84.2%, with 88.3% sensitivity for malignancy. Diagnostic performance were comparable across Single-criteria, Dual-criteria, and Triple-criteria groups ( CONCLUSION: This prospective multi-centre study introduced the concept of C-PPN, establishing a valuable reference for subsequent research. Moreover, the novel system featuring ultra-thin catheters demonstrated superior performance, achieving 100% navigation success, 84.2% diagnostic yield and 0 pneumothorax, in such nodules without radiation guidance.
3. Long-Term Mortality After Tuberculosis Among People With Disabilities in Korea.
Linking national registries for 305,055 TB survivors, disability was present in 10.1% and associated with markedly higher long-term mortality (e.g., 46.3 vs 16.3 per 1,000 person-years). Findings highlight a vulnerable subgroup needing tailored post-TB care and surveillance.
Impact: Quantifies excess long-term mortality among TB survivors with disabilities at national scale, informing equitable post-TB care models and policy prioritization.
Clinical Implications: Integrate disability status into post-TB follow-up protocols, prioritize rehabilitation and comorbidity management, and allocate resources for targeted surveillance to reduce preventable mortality.
Key Findings
- Nationwide cohort of 305,055 TB patients who survived at least one year was analyzed using linked registries.
- Disability was present in 10.1% of survivors and associated with substantially higher long-term mortality (e.g., 46.3 vs 16.3 per 1,000 person-years).
- Elevated mortality persisted across subgroups, supporting disability-informed post-TB care.
Methodological Strengths
- Very large, nationwide, population-based cohort with registry linkage.
- Use of Cox models with subgroup and sensitivity analyses by disability type and severity.
Limitations
- Observational design; potential unmeasured confounding and cause-of-death misclassification.
- Limited clinical granularity on post-TB sequelae and care pathways.
Future Directions: Develop and test disability-informed post-TB care bundles and evaluate their impact on mortality and quality of life in pragmatic trials.
BACKGROUND: Given the increased vulnerability of people with disabilities to poor health outcomes, we evaluated the impact of disability on long-term mortality among tuberculosis (TB) survivors. METHODS: We conducted a nationwide population-based cohort study using the linked national registry databases in the Republic of Korea. The study included 305,055 TB patients diagnosed between 2008 and 2016 who survived at least 1 year. The primary outcome was to compare long-term mortality after TB diagnosis between people with and without disabilities. Long-term mortality was defined as all-cause mortality at least 1 year after TB diagnosis. Cox proportional hazard models were used to evaluate the risk of long-term mortality. Subgroup and sensitivity analyses were performed based on disability type, severity, and cause of death. RESULTS: Disabilities were present in 10.1% of survivors and were associated with higher mortality rates (46.3 vs. 16.3 per 1,000 person-years, CONCLUSION: Long-term mortality risk is significantly higher in TB survivors with disabilities.